159992 创新药
已收盘 01-15 15:00:00
资讯
新帖
简况
15个月的蹉跎，宜明昂科如何用一个“迟到”的资产敲开MNC大门？｜创新药观察
华夏时报网 · 14:02
15个月的蹉跎，宜明昂科如何用一个“迟到”的资产敲开MNC大门？｜创新药观察
【券商聚焦】华泰证券：超预期创新药BD带动板块共振
金吾财讯 · 08:57
【券商聚焦】华泰证券：超预期创新药BD带动板块共振
微芯生物（688321）披露拟募资不超9.5亿元用于创新药研发及生产基地建设，1月14日股价上涨1.85%
证券之星 · 01-14 22:18
微芯生物（688321）披露拟募资不超9.5亿元用于创新药研发及生产基地建设，1月14日股价上涨1.85%
长城基金梁福睿：2026年创新药板块仍有望延续良好表现
新浪基金 · 01-14 18:26
长城基金梁福睿：2026年创新药板块仍有望延续良好表现
普洛药业：创新药索法地尔III期临床试验已终止
证券之星 · 01-14 17:21
普洛药业：创新药索法地尔III期临床试验已终止
老虎国际：维持恒指今年目标30000点 看好创新药、平台及新消费股
智通财经 · 01-14 14:06
老虎国际：维持恒指今年目标30000点 看好创新药、平台及新消费股
招银国际：料创新药出海趋势长期将延续 推荐买入中生制药、药明合联等
智通财经 · 01-14 11:38
招银国际：料创新药出海趋势长期将延续 推荐买入中生制药、药明合联等
港股异动 | 晶泰控股(02228)再涨超4% ReviR创新药RTX-117获中美临床批件
智通财经 · 01-14 10:01
港股异动 | 晶泰控股(02228)再涨超4% ReviR创新药RTX-117获中美临床批件
千亿创新药巨头，又出手并购
中国基金报 · 01-13 21:07
千亿创新药巨头，又出手并购
先声再明冲刺港股IPO，聚焦肿瘤创新药，对外授权超28亿美元
时代周报 · 01-13 15:19
先声再明冲刺港股IPO，聚焦肿瘤创新药，对外授权超28亿美元
创新药BD热潮引爆港股医药板块，机构：港股创新药估值仍具有较高的吸引力
券商中国 · 01-13 13:42
创新药BD热潮引爆港股医药板块，机构：港股创新药估值仍具有较高的吸引力
创新药重磅！最高390亿元！一周五个BD，核心资产驱动不断
券商中国 · 01-13 13:12
创新药重磅！最高390亿元！一周五个BD，核心资产驱动不断
“K药”专利倒计时 默沙东(MRK.US)亮出百亿美元“肌肉”! 欲在创新药领域掀起收购巨浪
智通财经 · 01-13 12:37
“K药”专利倒计时 默沙东(MRK.US)亮出百亿美元“肌肉”! 欲在创新药领域掀起收购巨浪
海翔药业（002099）披露签订创新药合作协议，1月12日股价上涨3.06%
证券之星 · 01-12 22:32
海翔药业（002099）披露签订创新药合作协议，1月12日股价上涨3.06%
海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作
证券之星 · 01-12 19:01
海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作
【券商聚焦】海通国际：市场对2026年创新药产业链情绪偏积极 看好荣昌生物等
金吾财讯 · 01-12 15:45
【券商聚焦】海通国际：市场对2026年创新药产业链情绪偏积极 看好荣昌生物等
创新药板块的强心剂! Piper Sandler押注“基因沉默”领军者Arrowhead(ARWR.US) 预言股价将狂飙55%
智通财经 · 01-12
创新药板块的强心剂! Piper Sandler押注“基因沉默”领军者Arrowhead(ARWR.US) 预言股价将狂飙55%
天风·医药 | 炎症性肠病——市场空间大，研发路径愈发清晰，中国创新药公司有望深度参与
天风研究 · 01-10
天风·医药 | 炎症性肠病——市场空间大，研发路径愈发清晰，中国创新药公司有望深度参与
一图速览 | 当前为什么看好创新药？
华泰睿思 · 01-10
一图速览 | 当前为什么看好创新药？
海南海药最新公告：创新药派恩加滨片Ⅱa期临床试验研究结果发布
证券之星 · 01-09
海南海药最新公告：创新药派恩加滨片Ⅱa期临床试验研究结果发布
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159992","market":"SZ","secType":"STK","nameCN":"创新药","latestPrice":0.89,"timestamp":1768460598000,"preClose":0.896,"halted":0,"volume":629555600,"delay":0,"changeRate":-0.0067,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.006,"latestTime":"01-15 15:00:00","open":0.892,"high":0.904,"low":0.887,"amount":563000000,"amplitude":0.019,"askPrice":0.89,"askSize":34790,"bidPrice":0.889,"bidSize":7503,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768527000000},"marketStatusCode":5,"adr":0,"adjPreClose":0.896,"symbolType":"fund","openAndCloseTimeList":[[1768440600000,1768447800000],[1768453200000,1768460400000]],"highLimit":0.986,"lowLimit":0.806,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.411828,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159992","defaultTab":"news","newsList":[{"id":"2603675153","title":"15个月的蹉跎，宜明昂科如何用一个“迟到”的资产敲开MNC大门？｜创新药观察","url":"https://stock-news.laohu8.com/highlight/detail?id=2603675153","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603675153?lang=zh_cn&edition=full","pubTime":"2026-01-15 14:02","pubTimestamp":1768456945,"startTime":"0","endTime":"0","summary":"2024年8月，当宜明昂科-B（1541.HK）与AxionBio签署那份潜在总金额超20亿美元的授权协议时，市场曾为之振奋。这笔交易被视作这家港股创新药企国际化布局的关键一跃。然而，仅仅过去一年半，这趟高调的出海旅程便宣告终止。2026年1月初，宜明昂科-B（1541.HK）发布公告，正式收回双抗药物IMM2510与CTLA-4抗体IMM27M的全部全球权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601153620297575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620297575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2603262688","title":"【券商聚焦】华泰证券：超预期创新药BD带动板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2603262688","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603262688?lang=zh_cn&edition=full","pubTime":"2026-01-15 08:57","pubTimestamp":1768438620,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，步入2026年以来，港股创新药交易不足两周，但已如该机构预期迎来开门红。港股创新药板块流动性大幅修复，且随着JPM医药峰会本周拉开序幕，中国BD交易持续超预期，相比去年同期有较大增长。该机构认为开年以来的流动性修复将带来一波明确的创新药β行情，该机构看好突破前高。外需型CXO在新分子需求的驱动下，业绩持续超预期，有望和创新药实现共振。该机构建议策略上优选中美估值差距较大的创新药资产相应公司；受益于新分子药物（多肽、寡核苷酸及ADC）的涌现，外需型CXO龙头凭借充沛的在手订单+强劲的漏斗效应，整体业绩已进入加速上升通道。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973256","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","BK1610","LU1719994722.HKD","LU0819121731.USD","SG9999004220.SGD","LU2476274308.USD","LU0140636845.USD","LU1688375341.USD","LU1979443071.USD","LU1226288170.HKD","BK1574","BK1588","LU1961090484.USD","06978","LU0516422952.EUR","LU0856984785.SGD","06185","09926","01093","LU0823426480.USD","LU2097828714.EUR","LU1303224171.USD","01877","06160","LU1960683339.HKD","LU0348825331.USD","SG9999002463.SGD","LU0348783233.USD","159992","01801","LU2328871848.SGD","02142","02616","LU1251922891.USD","IE00BZ08YR35.GBP","BK0028","LU1934453819.USD","09995","LU0348827113.USD","LU1993786604.SGD","LU0561508036.HKD","01177","IE00BPRC5H50.USD","09688","601688","LU2488822045.USD","LU1064131003.USD","LU0072913022.USD","BK1515","BK1161"],"gpt_icon":0},{"id":"2603614430","title":"微芯生物（688321）披露拟募资不超9.5亿元用于创新药研发及生产基地建设，1月14日股价上涨1.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603614430","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603614430?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:18","pubTimestamp":1768400297,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，微芯生物报收于34.7元，较前一交易日上涨1.85%，最新总市值为141.51亿元。该股当日开盘33.83元，最高36.22元，最低33.73元，成交额达8.2亿元，换手率为5.75%。公司近日发布公告称，深圳微芯生物科技股份有限公司拟向特定对象发行A股股票，募集资金总额不超过9.5亿元，用于创新药研发项目、彭州微芯原创新药制造基地（一阶段）项目及补充流动资金。本次发行股票数量不超过58,125,305股，不超过发行前总股本的30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","688321","BK0239","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2603923586","title":"长城基金梁福睿：2026年创新药板块仍有望延续良好表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2603923586","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603923586?lang=zh_cn&edition=full","pubTime":"2026-01-14 18:26","pubTimestamp":1768386360,"startTime":"0","endTime":"0","summary":"2026年开年以来，创新药板块强势回暖，板块关注度显著提升。一方面2026年小核酸领域迎来上市潮，为板块注入增量资金；另一方面创新药BD出海交易持续爆发，彰显全球市场对中国创新药的认可。我们来看长城医药产业精选基金经理梁福睿的分析。 梁福睿：长城医药产业精选成立于2024年10月，彼时二级市场刚经历完国庆节前的强势反弹，产品建仓初期受市场波动影响，短期业绩表现承压。未经长城基金管理有限公司事先书面许可，任何人","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-01-14/doc-inhhhnwv7147425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","159992","BK1161"],"gpt_icon":0},{"id":"2603769990","title":"普洛药业：创新药索法地尔III期临床试验已终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2603769990","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603769990?lang=zh_cn&edition=full","pubTime":"2026-01-14 17:21","pubTimestamp":1768382474,"startTime":"0","endTime":"0","summary":"证券之星消息，普洛药业(000739)01月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，公司目前的创新药索法地尔进衣如何？请详细介绍，谢谢！普洛药业回复：投资者您好！公司的创新药注射用索法地尔的 III 期临床试验，基于临床研究进展及后续研发投入等因素的综合评估，已于2024年终止，详见公司公告（公告编号：2024-02）。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400028961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","000739","BK0239","BK0188","BK0060","159992","06978"],"gpt_icon":0},{"id":"2603617026","title":"老虎国际：维持恒指今年目标30000点 看好创新药、平台及新消费股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603617026","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603617026?lang=zh_cn&edition=full","pubTime":"2026-01-14 14:06","pubTimestamp":1768370760,"startTime":"0","endTime":"0","summary":"老虎国际全球合伙人徐杨指出，上半年对港股、A股较有信心，其中，在港股中，创新药、互联网平台股、新消费股会较看好。虽然股市今年开局畅旺，他称暂时维持今年恒指目标30000点;A股则为5000 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260114/c674003052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2603663404","title":"招银国际：料创新药出海趋势长期将延续 推荐买入中生制药、药明合联等","url":"https://stock-news.laohu8.com/highlight/detail?id=2603663404","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603663404?lang=zh_cn&edition=full","pubTime":"2026-01-14 11:38","pubTimestamp":1768361880,"startTime":"0","endTime":"0","summary":"招银国际发布研报称，MSCI中国医疗指数今年初至今累计上涨11.8%，跑赢MSCI中国指数9.1%。医药行业显著上涨，主要由于去年第四季度行业回调消化了估值，年初机构投资者的配置意愿较强。展望2 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260114/c674001198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2603574366","title":"港股异动 | 晶泰控股(02228)再涨超4% ReviR创新药RTX-117获中美临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2603574366","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603574366?lang=zh_cn&edition=full","pubTime":"2026-01-14 10:01","pubTimestamp":1768356115,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，晶泰控股再涨超4%，月内累计涨幅接近50%。ReviR将继续完成RTX-117的后续临床开发，晶泰科技有权参与该管线的销售分成及后续授权收益分成。该行认为RTX-117临床获批标志其技术平台进入价值兑现期，随着合作管线梯队持续扩容，业绩弹性与估值重塑空间广阔。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392564.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","IE00B775SV38.USD","LU1366192091.USD","LU1929549753.HKD","IE00B3S45H60.SGD","02228","BK4550","LU1162221912.USD","BK4187","BK4585","RTX","BK1141","159992","BK4588","BK1617","LU1430594728.SGD","LU1280957306.USD","BK4566","BK1161","LU0683600562.USD","LU0640476718.USD","06978","LU1585245621.USD","LU0787776722.HKD","LU0320765646.SGD"],"gpt_icon":0},{"id":"2603684630","title":"千亿创新药巨头，又出手并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684630","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603684630?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:07","pubTimestamp":1768309620,"startTime":"0","endTime":"0","summary":"【导读】中国生物制药以12亿元人民币收购赫吉亚生物100%股权在2025年7月以约35亿元人民币收购礼新医药之后，中国生物制药于2026年1月13日晚发布公告称，以12亿元人民币收购赫吉亚生物100%股 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260113/c673987057.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260113/c673987057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2603505829","title":"先声再明冲刺港股IPO，聚焦肿瘤创新药，对外授权超28亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603505829","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603505829?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:19","pubTimestamp":1768288740,"startTime":"0","endTime":"0","summary":"来源丨时代商业研究院2026年1月9日，先声再明医药股份有限公司（以下简称“先声再明”）正式向港交所递交招股说明书，拟主板挂牌上市，中金公司和摩根士丹利担任联席保荐人。作为中国肿瘤领 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260113/c673969793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2603577028","title":"创新药BD热潮引爆港股医药板块，机构：港股创新药估值仍具有较高的吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2603577028","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603577028?lang=zh_cn&edition=full","pubTime":"2026-01-13 13:42","pubTimestamp":1768282920,"startTime":"0","endTime":"0","summary":"创新药迎来利好！ 根据 公告，1月12日，公司与 就RC148——一款新型靶向PD-1/VEGF的双特异性抗体药物签署独家授权许可协议，本次交易总额最高为56亿美元，首付款为6.5亿美元。首此消息提振，荣昌生物A股20%涨停，荣昌生物港股大涨近10%。 据券商统计，创新药在一周内落地5个BD。 受此带动，今天创新药成为市场主角。目前港股创新药估值虽然不在历史底部，但是相比全球同类产品估值具有较高的吸引力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-01-13/doc-inhhcszr7590851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","06978","159718"],"gpt_icon":0},{"id":"2603572166","title":"创新药重磅！最高390亿元！一周五个BD，核心资产驱动不断","url":"https://stock-news.laohu8.com/highlight/detail?id=2603572166","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603572166?lang=zh_cn&edition=full","pubTime":"2026-01-13 13:12","pubTimestamp":1768281120,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 创新药迎来利好！ 根据荣昌生物公告，1月12日，公司与艾伯维集团控股公司就RC148——一款新型靶向PD-1/VEGF的双特异性抗体药物签署独家授权许可协议，本次交易总额最高为56亿美元，首付款为6.5亿美元。 受此带动，今天创新药成为市场主角。A股创新药板块上涨超2.7%。1月12日，二代IO疗法更是发生三件大事。 有券商统计称，创新药一周内落地5个BD。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-01-13/doc-inhhcszz5009869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2603574289","title":"“K药”专利倒计时 默沙东(MRK.US)亮出百亿美元“肌肉”! 欲在创新药领域掀起收购巨浪","url":"https://stock-news.laohu8.com/highlight/detail?id=2603574289","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603574289?lang=zh_cn&edition=full","pubTime":"2026-01-13 12:37","pubTimestamp":1768279020,"startTime":"0","endTime":"0","summary":"美国医药巨头默沙东(MRK.US)希望达成更多的大规模交易，并强调看到了“数笔数百亿美元”级别的重大收购机遇，该公司CEO的最新言论意味着默沙东大概率将以最简单粗暴的“砸钱收购”方式在“K ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/usstock/20260113/c673967221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159992"],"gpt_icon":0},{"id":"2602469615","title":"海翔药业（002099）披露签订创新药合作协议，1月12日股价上涨3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602469615","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602469615?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:32","pubTimestamp":1768228336,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，海翔药业报收于7.4元，较前一交易日上涨3.06%，最新总市值为119.78亿元。近日，浙江海翔药业股份有限公司与万邦德制药集团有限公司签订《创新药合作协议》。海翔药业作为资金提供方，将投入1.5亿元人民币，获得WP205产品全球商业化收益的15%。若2027年6月30日前未能启动III期临床或获得上市许可，海翔药业有权终止协议，万邦德制药需返还全部款项并支付年化3%资金使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200037474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","002099","BK0028","BK0239","BK1161","BK0192","BK0188","BK0077","06978"],"gpt_icon":0},{"id":"2602519380","title":"海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519380","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602519380?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215702,"startTime":"0","endTime":"0","summary":"海翔药业(002099.SZ)公告称，公司与万邦德制药签订《创新药合作协议》，双方将围绕渐冻症适应症开展相关合作，包括WP205产品的研发和商业化。海翔药业将提供1.5亿元资金，并享有产品商业化后15%的收益权益。该协议需经万邦德医药控股集团股份有限公司股东会审议通过后生效。存在法规政策、市场环境等风险，以及药品研发的高风险特点。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200029909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1191","BK0239","BK0188","BK0028","BK0050","01477","06978","002099","159992","BK0004","BK0077","BK0192","002082","BK1574"],"gpt_icon":0},{"id":"2602659414","title":"【券商聚焦】海通国际：市场对2026年创新药产业链情绪偏积极 看好荣昌生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2602659414","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602659414?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:45","pubTimestamp":1768203955,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际研报指出，上周恒生医疗保健指数上涨10.3%，跑赢恒生指数10.7个百分点。2026年年初以来，恒生医疗保健指数涨幅为12.4%，跑赢恒生指数10.0个百分点。该机构指出，上周部分细分板块龙头显著反弹，主要归因于：一方面，前期获利了结资金影响逐步出清；另一方面，市场对2026年创新药产业链情绪偏积极，看好管线优质和推进速度快、有BD潜力、股价位置合理的板块龙头，如荣昌生物、映恩生物等。同时，受到AI主题热度高涨影响，AI医疗概念走强，高增速、业绩兑现度高的主题标的医脉通、平安好医生涨幅明显。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973039","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1142","BK1574","09606","LU1064130708.USD","09995","BK1161","BK1247","LU2148510915.USD","BK1617","LU1969619763.USD","BK1583","02192","HK0000252152.HKD","688331","01833","BK1571","BK0239","BK1587","BK1515","HK0000500386.USD","LU0049112450.USD","BK1615","BK1219","LU2328871848.SGD","BK1189","LU1064131003.USD","LU1235295612.USD","06978","HK0000252160.HKD","LU2543165471.USD","LU1046422090.SGD","159992"],"gpt_icon":0},{"id":"2602560433","title":"创新药板块的强心剂! Piper Sandler押注“基因沉默”领军者Arrowhead(ARWR.US) 预言股价将狂飙55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602560433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602560433?lang=zh_cn&edition=full","pubTime":"2026-01-12 12:01","pubTimestamp":1768190468,"startTime":"0","endTime":"0","summary":"Piper Sandler予以Arrowhead Pharmaceuticals的100美元这一12个月内无比强劲的看涨目标价位，堪称对于当前处于回调阶段的全球创新药领域的一针重磅强心剂。今年以来Arrowhead Pharmaceuticals股价表现不佳，年内迄今跌近3%，大幅跑输标普500指数。这也是Arrowhead的第一款获得FDA批准上市的药物，标志着其从临床阶段向商业化阶段的转变。该公司推出了用于FCS的Redemplo，来自Piper Sandler的分析师Edward Tenthoff指出。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","06978","BK4588","BK4139","BK4585","159992","ARWR"],"gpt_icon":0},{"id":"2602458720","title":"天风·医药 | 炎症性肠病——市场空间大，研发路径愈发清晰，中国创新药公司有望深度参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2602458720","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602458720?lang=zh_cn&edition=full","pubTime":"2026-01-10 17:00","pubTimestamp":1768035600,"startTime":"0","endTime":"0","summary":"IBD的患者人群庞大，且存在未满足的治疗需求，2024年药物销售规模约240亿美金。现有治疗药物中，乌帕替尼综合疗效最优，但存在安全性问题。中国创新药公司有望深度参与IBD大赛道。2024年IBD患者数量接近91万人，并预计2025年患者数将达150万，由少见病走向常见病。中国创新药公司有望深度参与IBD大赛道在前沿靶点上，中国药企在TL1A方向储备较多，有超20款药物在研，覆盖单抗与双抗等形态。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649150073&idx=3&sn=33ddf17fa4338eb2ef1ebec896a293b3&chksm=825e9afb02658828265e79311851b2ded48fd57cb041b4d431b7d1514651f9ac3bc8e49526b2&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159992","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2602818945","title":"一图速览 | 当前为什么看好创新药？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602818945","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602818945?lang=zh_cn&edition=full","pubTime":"2026-01-10 11:28","pubTimestamp":1768015680,"startTime":"0","endTime":"0","summary":"相关研报：华泰 | 医药：看好创新药流动性修复叠加多重催化","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649840617&idx=3&sn=f34c64b257b171a43bcdf615bc43d4b9&chksm=893fdacb440c67cf65fb0d03148258317031c229d87eaca19f741a231492cee96307980b7089&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159992","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2602754883","title":"海南海药最新公告：创新药派恩加滨片Ⅱa期临床试验研究结果发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2602754883","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602754883?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:50","pubTimestamp":1767963010,"startTime":"0","endTime":"0","summary":"海南海药(000566.SZ)公告称，公司全资子公司海口市制药厂有限公司与中国科学院上海药物研究所联合研究开发的创新药派恩加滨项目，于近日完成了Ⅱa期临床试验，初步研究结果显示达到主要及次要临床终点。派恩加滨属于化药1类，为新型抗癫痫药物，新一代KCNQ钾通道激动剂，目前全球尚无上市品种，本品可用于难治性癫痫的治疗。本次仅为派恩加滨完成中国Ⅱa期临床试验结果分析，后续尚需完成Ⅱb期及Ⅲ期临床试验，并经国家药监局批准后方可上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900038074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","000566","BK0146","06978","BK0060","BK0070","BK1574","BK0239","BK1161","BK0188"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768462880760,"stockEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0529},{"period":"3month","weight":-0.0261},{"period":"6month","weight":0.0193},{"period":"1year","weight":0.3274},{"period":"ytd","weight":0.0782}],"compareEarnings":[{"period":"1week","weight":0.0099},{"period":"1month","weight":0.0667},{"period":"3month","weight":0.0536},{"period":"6month","weight":0.1674},{"period":"1year","weight":0.2731},{"period":"ytd","weight":0.0396}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创新药,159992,创新药股票,创新药股票老虎,创新药股票老虎国际,创新药行情,创新药股票行情,创新药股价,创新药股市,创新药股票价格,创新药股票交易,创新药股票购买,创新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创新药(159992)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创新药(159992)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}